表柔比星联合多西他赛化疗对乳腺癌根治术后患者的治疗效果

Therapeutic Effect of Epirubicin Combined with Docetaxel for Chemotherapy on Patients After Radical Mastectomy for Breast Cancer

目的探讨表柔比星联合多西他赛化疗治疗乳腺癌根治术后患者的效果和安全性。方法80例行乳腺癌根治术患者随机分为两组。术后,参照组采用FEC方案进行化疗,研究组采用表柔比星+多西他赛进行化疗。比较两组的肿瘤血管相关生长因子、不良反应以及远期复发率。结果化疗后,研究组的血清VEGF、ANG2水平均低于参照组(P<0.05)。研究组化疗过程中的胃肠功能损害发生率低于参照组(P<0.05)。随访3年期间,研究组的复发率为22.50%,低于参照组的47.50%(P<0.05)。结论表柔比星联合多西他赛化疗可明显抑制乳腺癌根治术后患者肿瘤血管相关生长因子表达,降低术后复发风险。

Objective To explore the effect and safety of epirubicin combined with docetaxel for chemotherapy in the treatment of patients after radical mastectomy for breast cancer.Methods 80 patients undergoing radical mastectomy were randomly divided into two groups.After surgery,the reference group was treated with FEC regimen for chemotherapy,and the study group was treated with epirubicin+docetaxel for chemotherapy.The tumor vascular related growth factors,adverse reactions and long-term recurrence rate were compared between the two groups.Results After chemotherapy,the levels of serum VEGF and ANG2 in the study group were lower than those in the reference group(P<0.05).The incidence of gastrointestinal function damage during chemotherapy in the study group was lower than that in the reference group(P<0.05).During the 3-year follow-up,the recurrence rate in the study group was 22.50%,lower than 47.50%in the reference group(P<0.05).Conclusions Epirubicin combined with docetaxel for chemotherapy can significantly inhibit the expressions of tumor vascular related growth factors in patients after radical mastectomy for breast cancer and reduce the risk of postoperative recurrence.